Marilactone

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

Marilactone
Category Others
Catalog number BBF-04448
CAS 34818-17-2
Molecular Weight 154.16
Molecular Formula C8H10O3
Purity ≥98%

Online Inquiry

Description

Marilactone is produced from the fungus Stachylidium sp.

Specification

Synonyms 2H-Pyran-2-one, 6-ethyl-4-hydroxy-3-methyl-; 3-Methyl-4-hydroxy-6-ethyl-2-pyron
Storage Store at 2-8°C
IUPAC Name 6-ethyl-4-hydroxy-3-methylpyran-2-one
Canonical SMILES CCC1=CC(=C(C(=O)O1)C)O
InChI InChI=1S/C8H10O3/c1-3-6-4-7(9)5(2)8(10)11-6/h4,9H,3H2,1-2H3
InChI Key USMZMYPGRVEPNO-UHFFFAOYSA-N

Properties

Appearance Powder
Boiling Point 260.1±40.0°C (Predicted)
Melting Point 180°C
Density 1.194±0.06 g/cm3 (Predicted)
Solubility Soluble in Chloroform

Reference Reading

1. Unprecedented polyketides from a marine sponge-associated Stachylidium sp
Celso Almeida, Ekaterina Eguereva, Stefan Kehraus, Gabriele M König J Nat Prod. 2013 Mar 22;76(3):322-6. doi: 10.1021/np300668j. Epub 2012 Dec 26.
From the marine sponge-derived fungus Stachylidium sp. six novel phthalide-related compounds, cyclomarinone (1), maristachones A-E (2-5), and marilactone (6), were isolated. The structure of compound 1 comprises a hydroxycyclopentenone ring instead of the furanone ring characteristic for phthalides and represents a new carbon arrangement within polyketides. In the epimeric compounds 5a and 5b the phthalide (=isobenzofuranone) nucleus is modified to an isobenzofuran ring with ketal and acetal functionalities. Biosynthetically the structural skeletons of cyclomarinone (1) and maristachones A (2), C (4), D (5a), and E (5b) are most unusual due to the presence of an additional carbon atom when compared to the basic polyketide skeleton. This special biosynthetic feature also holds true for the likewise isolated polyketide marilactone (6).
2. Cost-effectiveness of rivaroxaban versus warfarin in non-valvular atrial fibrillation patients with chronic kidney disease in China
Lin Liu, Dongsheng Hong, Kuifen Ma, Xiaoyang Lu J Clin Pharm Ther. 2021 Jun;46(3):658-668. doi: 10.1111/jcpt.13318. Epub 2020 Nov 23.
What is known and objective: In non-valvular atrial fibrillation (NVAF) patients with chronic kidney disease (CKD), rivaroxaban was not inferior to warfarin in preventing stroke and systemic embolism. However, a comparative evaluation of the cost-effectiveness of rivaroxaban and warfarin therapies for NVAF patients at different renal function levels has not yet been reported, and this study aimed to estimate the cost-effectiveness of rivaroxaban compared with warfarin in Chinese NVAF patients with CKD. Methods: A Markov model was constructed to estimate quality-adjusted life years (QALYs) and lifetime costs associated with the use of rivaroxaban relative to warfarin in patients with NVAF at different estimated glomerular filtration rate (eGFR) levels as follows: 30 to 80% that the ICER would be lower than the willingness-to-pay threshold of three times the GDP of China in 2019 in all the subgroups. Results were consistent even under the assumption of anticoagulant discontinuation after major bleeding events. The model was most sensitive to event-free-related utility and survival rates. What is new and conclusion: The existing evidence supports the cost-effectiveness of rivaroxaban therapy as an alternative anticoagulant to warfarin for patients with NVAF at different renal function levels.

Recommended Products

Bio Calculators

Stock concentration: *
Desired final volume: *
Desired concentration: *

L

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2

* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O c22h30n40
g/mol
g

Recently viewed products

Online Inquiry

Verification code

Copyright © 2024 BOC Sciences. All rights reserved.

cartIcon
Inquiry Basket